GT201000298A - 2,6-diamino-pirimidin-z-il-carboxamidas como inhibidores de syk o jak quinasas - Google Patents
2,6-diamino-pirimidin-z-il-carboxamidas como inhibidores de syk o jak quinasasInfo
- Publication number
- GT201000298A GT201000298A GT201000298A GT201000298A GT201000298A GT 201000298 A GT201000298 A GT 201000298A GT 201000298 A GT201000298 A GT 201000298A GT 201000298 A GT201000298 A GT 201000298A GT 201000298 A GT201000298 A GT 201000298A
- Authority
- GT
- Guatemala
- Prior art keywords
- carboxamids
- jak
- diamino
- inhibitors
- kinasas
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Oncology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
LA PRESENTE INVENCIÓN SE RELACIONA CON COMPUESTOS DERIVADOS DE 2,6-DIAMINO-PIRIMIDIN-5-IL-CARBOXAMIDAS, A SALES FARMACÉUTICAMENTE ACEPTABLES, TAUTÓMEROS, ESTEREOISÓMEROS, Y SU USO COMO INHIBIDORES DE JAK QUINASAS.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US4539908P | 2008-04-16 | 2008-04-16 | |
US4541708P | 2008-04-16 | 2008-04-16 | |
US4540608P | 2008-04-16 | 2008-04-16 | |
US12034108P | 2008-12-05 | 2008-12-05 | |
US12034408P | 2008-12-05 | 2008-12-05 | |
US12034808P | 2008-12-05 | 2008-12-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
GT201000298A true GT201000298A (es) | 2014-05-07 |
Family
ID=43570275
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GT201000298A GT201000298A (es) | 2008-04-16 | 2010-10-15 | 2,6-diamino-pirimidin-z-il-carboxamidas como inhibidores de syk o jak quinasas |
Country Status (18)
Country | Link |
---|---|
AU (1) | AU2009251863B2 (es) |
BR (1) | BRPI0910560B8 (es) |
CO (1) | CO6331433A2 (es) |
CY (1) | CY1118559T1 (es) |
DK (1) | DK2321283T3 (es) |
ES (1) | ES2597441T3 (es) |
GT (1) | GT201000298A (es) |
HK (1) | HK1158179A1 (es) |
HU (1) | HUE031638T2 (es) |
IL (3) | IL208637A (es) |
LT (1) | LT2321283T (es) |
MX (1) | MX353206B (es) |
NI (1) | NI201000176A (es) |
NZ (1) | NZ589314A (es) |
PL (1) | PL2321283T3 (es) |
PT (1) | PT2321283T (es) |
SI (1) | SI2321283T1 (es) |
ZA (1) | ZA201007045B (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
ES2711249T3 (es) | 2008-06-27 | 2019-04-30 | Celgene Car Llc | Compuestos de heteroarilo y usos de los mismos |
AU2013202496B2 (en) * | 2008-06-27 | 2016-08-04 | Celgene Car Llc | Heteroaryl compounds and uses thereof |
KR20130099040A (ko) | 2010-08-10 | 2013-09-05 | 셀진 아빌로믹스 리서치, 인코포레이티드 | Btk 억제제의 베실레이트 염 |
WO2014124230A2 (en) | 2013-02-08 | 2014-08-14 | Celgene Avilomics Research, Inc. | Erk inhibitors and uses thereof |
EP3179858B1 (en) | 2014-08-13 | 2019-05-15 | Celgene Car Llc | Forms and compositions of an erk inhibitor |
CN114196651B (zh) * | 2021-12-15 | 2023-06-30 | 中国林业科学研究院亚热带林业研究所 | D6蛋白激酶d6pkl2的新用途 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6432963B1 (en) * | 1997-12-15 | 2002-08-13 | Yamanouchi Pharmaceutical Co., Ltd. | Pyrimidine-5-carboxamide derivatives |
MXPA04012855A (es) * | 2002-06-28 | 2005-04-19 | Yamanouchi Pharma Co Ltd | Derivado de diaminopirimidincarboxiamida. |
JP2009544592A (ja) * | 2006-07-21 | 2009-12-17 | ノバルティス アクチエンゲゼルシャフト | Jakキナーゼ阻害剤としての2,4−ジ(アリールアミノ)−ピリミジン−5−カルボキサミド化合物 |
-
2009
- 2009-04-16 NZ NZ589314A patent/NZ589314A/xx not_active IP Right Cessation
- 2009-04-16 MX MX2010011464A patent/MX353206B/es active IP Right Grant
- 2009-04-16 ES ES09755219.4T patent/ES2597441T3/es active Active
- 2009-04-16 PT PT97552194T patent/PT2321283T/pt unknown
- 2009-04-16 DK DK09755219.4T patent/DK2321283T3/en active
- 2009-04-16 LT LTEP09755219.4T patent/LT2321283T/lt unknown
- 2009-04-16 PL PL09755219T patent/PL2321283T3/pl unknown
- 2009-04-16 HU HUE09755219A patent/HUE031638T2/en unknown
- 2009-04-16 BR BRPI0910560A patent/BRPI0910560B8/pt active IP Right Grant
- 2009-04-16 AU AU2009251863A patent/AU2009251863B2/en active Active
- 2009-04-16 SI SI200931540A patent/SI2321283T1/sl unknown
-
2010
- 2010-10-04 ZA ZA2010/07045A patent/ZA201007045B/en unknown
- 2010-10-11 IL IL208637A patent/IL208637A/en active IP Right Grant
- 2010-10-15 GT GT201000298A patent/GT201000298A/es unknown
- 2010-10-15 NI NI201000176A patent/NI201000176A/es unknown
- 2010-11-16 CO CO10143190A patent/CO6331433A2/es active IP Right Grant
-
2011
- 2011-11-16 HK HK11112350.6A patent/HK1158179A1/zh not_active IP Right Cessation
-
2016
- 2016-10-13 CY CY20161101026T patent/CY1118559T1/el unknown
-
2017
- 2017-04-09 IL IL251655A patent/IL251655B/en active IP Right Grant
-
2020
- 2020-05-07 IL IL274522A patent/IL274522A/en unknown
Also Published As
Publication number | Publication date |
---|---|
HUE031638T2 (en) | 2017-07-28 |
ZA201007045B (en) | 2012-08-29 |
IL208637A (en) | 2017-04-30 |
DK2321283T3 (en) | 2016-10-31 |
HK1158179A1 (zh) | 2012-07-13 |
ES2597441T3 (es) | 2017-01-18 |
CO6331433A2 (es) | 2011-10-20 |
BRPI0910560B8 (pt) | 2023-03-21 |
CY1118559T1 (el) | 2017-07-12 |
BRPI0910560B1 (pt) | 2023-01-24 |
LT2321283T (lt) | 2016-12-12 |
NZ589314A (en) | 2012-10-26 |
MX2010011464A (es) | 2014-06-16 |
AU2009251863A1 (en) | 2009-12-03 |
IL251655B (en) | 2020-05-31 |
AU2009251863B2 (en) | 2014-09-25 |
PL2321283T3 (pl) | 2017-01-31 |
SI2321283T1 (sl) | 2017-01-31 |
IL208637A0 (en) | 2010-12-30 |
IL274522A (en) | 2020-06-30 |
PT2321283T (pt) | 2016-10-19 |
AU2009251863A2 (en) | 2011-06-09 |
MX353206B (es) | 2018-01-08 |
IL251655A0 (en) | 2017-06-29 |
NI201000176A (es) | 2011-08-08 |
BRPI0910560A2 (pt) | 2021-04-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE517107T1 (de) | Pyrrolopyrazinkinaseinhibitoren | |
CO6311079A2 (es) | Derivados de aminodihidrotiazina como inhibidores de la enzima bace para el tratamiento de la enfermedad de alzheimer | |
ATE522536T1 (de) | Pyrrolopyrazin-kinasehemmer | |
CY1118969T1 (el) | Ενωσεις πυριμιδινο-2-αμινης και η χρηση τους ως αναστολεις των κινασων jak | |
CR20130023A (es) | Pirazolo[1,5-a]pirimidinas para tratamiento antiviral | |
UY33227A (es) | Compuestos de pirrolopirimidina como inhibidores de la cdk4/6 | |
CR11803A (es) | Pirrolopiridinas como inhibidores de cinasa | |
CO6321282A2 (es) | Derivados de piperidinilindol como inhibidores de aldosterona sintasa | |
ECSP109922A (es) | Compuestos de pirazol y su uso como inhibidores raf | |
CO6480927A2 (es) | Derivados de imidazolin-2-ona 1,3-disustituida como inhibidores de cyp17. | |
CO6361936A2 (es) | Imidazopiridazinacarbonitrilos utiles como inhibidores de quinasa | |
TW200942543A (en) | Pyrrolopyrazine kinase inhibitors | |
CR20110620A (es) | Derivados de n-(hetero)aril-pirrolidina de pirazo-4-il-pirrolo[2,3-d]pirimidinas y pirrol-3-il-pirrolo[2,3-d]pirimidinas como ihnibidores de la quinasa janus | |
GT201000298A (es) | 2,6-diamino-pirimidin-z-il-carboxamidas como inhibidores de syk o jak quinasas | |
UY32585A (es) | Nuevos derivados del indazol utiles como inhibidores de la familia fosfoinositida 3´oh quinasa | |
ECSP10010271A (es) | Derivados de tiazol usados como inhibidores de pi 3-cinasa | |
CY1118093T1 (el) | Φαρμακοτεχνικες μορφες που περιλαμβανουν παραγωγα 1-(bhta-d-γλυκοπυρανοζυλ)-2-θειενυλμεθυλβενζολιου ως αναστολεις sglt | |
ATE522534T1 (de) | Pyrrolopyrazin-kinasehemmer | |
NI201200023A (es) | Derivados de 5-fluoropirimidinona | |
BR112012024117A2 (pt) | inibidores de pirrolopirazina quinase | |
MX2014002442A (es) | Inhibidores de pirrolopirazina cinasa. | |
UY33226A (es) | Compuestos de pirrolopirimidina deuterada como inhibidores de la cdk4/6 | |
EA201290632A1 (ru) | Производные бетулина | |
UY32748A (es) | 2-carboxamida-cicloamino-ureas | |
UY32042A (es) | Compuestos de 2-aminopirimidina como potentes inhibidores de hsp-90 |